Tango Therapeutics reports Q3 net income, revenue jumps

Tango Therapeutics

04/11/2025 14:07

Overview

Tango Therapeutics Q3 collaboration revenue increased significantly compared to the same period in 2024

Company reports Q3 net income, reversing a net loss from the previous year

$225 mln financing extends cash runway into 2028, supporting clinical trials

Outlook

Company anticipates pivotal trial for vopimetostat in 2L MTAP-del pancreatic cancer in 2026

Initial safety and efficacy data from vopimetostat + RAS(ON) inhibitors expected in 2026

$225 mln financing extends Tango's cash runway into 2028

Result Drivers

COLLABORATION REVENUE INCREASE - Significant increase in collaboration revenue due to recognition of deferred revenue from Gilead collaboration

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$53.81 mln
Q3 Net Income
$15.88 mln
Q3 Basic EPS
$0.14
Q3 Operating Expenses
$39.73 mln
Q3 Operating Income
$14.07 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tango Therapeutics Inc is $12.50, about 35.9% above its November 3 closing price of $8.01

Press Release: ID:nGNXbhg20z

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)